Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
BelaRd trial: what clinicians have said so far
Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- NCT04808037 ↗
- Active, not recruiting
- Hellenic Society of Hematology
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on BelaRd (belantamab mafodotin plus lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BelaRd so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X | |
| 1 YouTube video | |
| 1 podcast episode |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Study of Belantamab Mafodotin in Combination With Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin
- Arms
- Cohort 1, First Part · Experimental
- Cohort 2, First Part · Experimental
- Cohort 3, First Part · Experimental
- Group A, Second Part · Experimental
- Group B, Second Part · Experimental
- Enrollment
- 66
- Primary outcomes
- Number of participants with dose-limiting toxicities (DLTs) in each of the cohorts 1-3
- Overall Response rate as per IMWG by Investigator Assessment, defined as the percentage of participants with a confirmed PR, VGPR, CR or sCR
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) in each of the cohorts 1-3
- Number of participants with adverse events (AEs) and serious adverse events (SAEs) in patients receiving the Recommended Phase 2 Dose
- Sponsor
- Hellenic Society of Hematology with GlaxoSmithKline
- Start
- Feb 22, 2021
- Primary completion
- Sep 8, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04808037 · updated Oct 24, 2023
Publications
linked from the registry- Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Kanellias N, Migkou M, Theodorakakou F, Spiliopoulou V, Solia E, Eleutherakis-Papaiakovou E, Psarros G, Kastritis E, Dimopoulos MA. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. Blood. 2026 Apr 2;147(14):1574-1583. doi: 10.1182/blood.2025031629. PubMed 41346230
- Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Spiliopoulou V, Kanellias N, Eleutherakis-Papaiakovou E, Roussou M, Psarros G, Kastritis E, Dimopoulos MA, Terpos E. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study. Am J Hematol. 2024 Mar;99(3):502-504. doi: 10.1002/ajh.27219. Epub 2024 Jan 25. No abstract available. PubMed 38270219